Efficacy and Safety Assessment of T1695 Ophthalmic Suspension, Versus Ciclosporin Ophthalmic Emulsion, in Participants With Moderate to Severe Vernal Keratoconjunctivitis (VKC)
Status: Recruiting
Location: See all (11) locations...
Intervention Type: Diagnostic test, Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY
The aim of the study is to Compare the Effectiveness and Safety of T1695 Versus Ciclosporin in Participants with Moderate to Severe Vernal Keratoconjunctivitis
Eligibility
Participation Requirements
Sex: All
Minimum Age: 4
Maximum Age: 17
Healthy Volunteers: f
View:
• Informed consent signed and dated
• Male or female participant from 4 years to less than 18 years old.
• Participant with grading score of 3 or 4 on the Bonini scale for clinical grading of VKC in each eye.
Locations
Other Locations
India
M&J Institute of Ophthalmology
NOT_YET_RECRUITING
Ahmedabad
Netralaya Super Speciality Eye Hospital
RECRUITING
Ahmedabad
Narayana Nethralaya
RECRUITING
Bangalore
L. V. Prasad Eye Institute (LVPEI)
RECRUITING
Hyderabad
Agrawal Hospital
RECRUITING
Jaipur
Disha Eye Hospitals - Barrackpore
RECRUITING
Kolkata
Regional Institute of Ophthalmology (RIO) - Kolkata
RECRUITING
Kolkata
Regional Institute of Ophthalmology, Patna
RECRUITING
Patna
PBMA'S H. V. Desai Eye Hospital
RECRUITING
Pune
Shivam Retina Clinic and Eye Hospital
RECRUITING
Surat
L V Prasad Eye Institute
RECRUITING
Visakhapatnam
Contact Information
Primary
Corentin LE CAMUS
Corentin.LECAMUS@theapharma.com
+33473981436
Time Frame
Start Date: 2026-03-24
Estimated Completion Date: 2027-01-21
Participants
Target number of participants: 120
Treatments
Experimental: T1695
The participant should instill T1695.
Active_comparator: Ciclosporin
The participant should instill Ciclosporin.
Related Therapeutic Areas
Sponsors
Leads: Laboratoires Thea